Pfizer planning to merge off-patent drug business with Mylan
30th Jul 2019

Pfizer is planning to merger its off-patent drug business with generic drugmaker Mylan to create a global leader in low-cost treatment. The new entity, which will be renamed upon the deal's closure, will have a portfolio that includes impotence drug Viagra, cholesterol pills Lipitor, painkiller Lyrica, and the life-saving EpiPen allergy treatment.

Pfizer has produced innovative breakthroughs in a wide range of research areas, including depression, erectile dysfunction, high cholesterol, HIV infection, hypertension, bacterial infections and systemic fungal infections.